



TATDN2 (K-17): sc-99660

BACKGROUND

TATDN2 (tatD DNase domain containing 2), whose alternative names include KIAA0218, putative deoxyribonuclease TATDN2, MGC126819 or MGC126825, is a 761 amino acid protein belonging to the tatD DNase family. TATDN2 localizes to the nucleus and is encoded by a gene mapping to human chromosome 3p25.3. Chromosome 3 houses over 1,100 genes, including a chemokine receptor (CKR) gene cluster and a variety of human cancer-related gene loci. Key tumor suppressing genes on chromosome 3 include those that encode the apoptosis mediator RASSF1, the cell migration regulator HYAL1 and the angiogenesis suppressor SEMA3B. Marfan syndrome, porphyria, von Hippel-Lindau syndrome, osteogenesis imperfecta and Charcot-Marie-Tooth disease are a few of the numerous genetic diseases associated with chromosome 3.

REFERENCES

1. De Jonghe, P., Timmerman, V., FitzPatrick, D., Spoelers, P., Martin, J.J. and Van Broeckhoven, C. 1997. Mutilating neuropathic ulcerations in a chromosome 3q13-q22 linked Charcot-Marie-Tooth disease type 2B family. *J. Neurol. Neurosurg. Psychiatr.* 62: 570-573.
2. Braga, E.A., Kashuba, V.I., Maliukova, A.V., Loginov, V.I., Senchenko, V.N., Bazov, I.V., Kiselev, L.L. and Zabarovski, E.R. 2003. New tumor suppressor genes in hot spots of human chromosome 3: new methods of identification. *Mol. Biol.* 37: 194-211.
3. Tsend-Ayush, E., Grütznér, F., Yue, Y., Grossmann, B., Hänsel, U., Sudbrak, R. and Haaf, T. 2004. Plasticity of human chromosome 3 during primate evolution. *Genomics* 83: 193-202.
4. Yue, Y., Grossmann, B., Ferguson-Smith, M., Yang, F. and Haaf, T. 2005. Comparative cytogenetics of human chromosome 3q21.3 reveals a hot spot for ectopic recombination in hominoid evolution. *Genomics* 85: 36-47.
5. Seim, I., Carter, S.L., Herington, A.C. and Chopin, L.K. 2008. Complex organisation and structure of the ghrelin antisense strand gene GHRLOS, a candidate non-coding RNA gene. *BMC Mol. Biol.* 9: 95.

CHROMOSOMAL LOCATION

Genetic locus: TATDN2 (human) mapping to 3p25.3.

SOURCE

TATDN2 (K-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of TATDN2 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-99660 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

TATDN2 (K-17) is recommended for detection of TATDN2 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for TATDN2 siRNA (h): sc-78024, TATDN2 shRNA Plasmid (h): sc-78024-SH and TATDN2 shRNA (h) Lentiviral Particles: sc-78024-V.

Molecular Weight of TATDN2: 85 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.